Elite Pharmaceuticals Appoints Aqeel A. Fatmi, Ph.D. to Its Board of Directors
07 août 2018 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today the appointment of Aqeel A. Fatmi, Ph.D. to its Board of...
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss Year-end Financial Results on June 15, 2018
11 juin 2018 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., June 11, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals and SunGen Pharma File ANDA for Extended-Release CNS Stimulant
30 mai 2018 07h30 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals Announces Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc., USA
29 mai 2018 07h30 HE
|
Elite Pharmaceuticals, Inc.; Glenmark Pharmaceuticals, Inc., USA
NORTHVALE, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc (OTCBB:ELTP) announced today the signing of a license, manufacturing, and supply agreement with Glenmark Pharmaceuticals,...
Visiongain Launches New Report on the Generic Drugs Market 2018-2028
21 mai 2018 07h34 HE
|
Visiongain Ltd
LONDON, May 21, 2018 (GLOBE NEWSWIRE) -- Visiongain has launched a new pharma report Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe,...
Elite Pharmaceuticals Reports Positive Topline Results from SequestOx™ Pilot Study
30 janv. 2018 08h35 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for...
Elite Pharmaceuticals Reports Positive Topline Results from Pivotal Bioequivalence Studies for an Extended-Release Generic
10 janv. 2018 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from pivotal bioequivalence studies for...
Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP
02 janv. 2018 12h56 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2018 Ended September 30, 2017
09 nov. 2017 16h59 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
Groundbreaking prescription tool helps Canadians compare clinical and cost-effectiveness of drugs
08 nov. 2017 09h43 HE
|
Reformulary Group
TORONTO, ON--(Marketwired - November 08, 2017) - Today, Reformulary Group, Canada's leading, independent drug plan management company, launched DrugFinder™, a consumer app that allows Canadians to...